Tune Therapeutics, a Durham, NC-based epigenome editing company, raised over $175M in Series B funding.
The round was led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation.
The company intends to use the funds to accelerate the development of its existing pipeline, currently anchored by Tune-401, its clinical-stage epigenetic silencing drug for chronic Hepatitis B (HBV).
Founded in 2021, Tune Therapeutics is an epigenome editing company developing Tune-401, which is an investigational product candidate for treating Hepatitis B (HBV) infection using its TEMPO platform to epigenetically silence viral HBV intDNA and cccDNA necessary for sustained HBV infection. Lipid nanoparticle technology for Tune-401 has been provided by Acuitas Therapeutics Inc.
In November of 2024, Tune announced it was moving to the clinical stage, having received approval to begin clinical trials in New Zealand, and subsequently in Hong Kong – supported by world-renowned hepatologists and Principal Investigators Dr. Ed Gane and Dr. Man-Fung Yuen, respectively.
FinSMEs
13/01/2025